Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and ...

Evernorth — the Cigna division that oversees the Express ... monthly copays for two popular weight-loss drugs, Wegovy and Zepbound, at $200. The impact on the employers' spending is unclear ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly sell their drugs to certain patients ...

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with ... copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

government and the industry to find creative solutions that help people with obesity access Zepbound." While Cigna would not discuss the actual discounts reached under the new Evernorth ...

Cigna Group’s drug benefit unit is offering ... patients would pay less than the cash price for Eli Lilly & Co.’s Zepbound or Novo Nordisk A/S’s Wegovy, but typically more than the normal ...

NEW YORK, May 21 (Reuters) - Cigna (CI.N), opens new tab will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its ...